drugset
Drugs / Levonadifloxacin
last change Aug 2020 re-read 9 days ago

Levonadifloxacin

also known as (s)-(-)-nadifloxacin · Levonadifloxacina · Levonadifloxacine · WCK-771 FREE BASE

Small molecule

Investigated by
Wockhardt

Trials 2

today NCT03405064 · Ph 3 NCT02244827 · Ph 1
2015201620172018201920202021202220232024202520262027
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 11 trial
Phase 1 NCT02244827 Sep → Dec 2014 liver disease, severe congenital Wockhardt Completed No outcome recorded
Phase 31 trial · 1 met primary
Phase 3 NCT03405064 Aug 2017 → Sep 2018 — Wockhardt Completed Met primary

News releases announcing trial results or a regulatory action · 1

DateIssuerRelease
2020-01-16 Wockhardt Regulatory INDIA’S FIRST NEW DISCOVERY ANTIBIOTICS FROM WOCKHARDT GRANTED INDIAN REGULATORY APPROVAL wockhardt.com ↗
India’s First New Discovery Antibiotics from Wockhardt Granted Indian Regulatory Approval

All press releases naming this drug 1 release

DateIssuerRelease

Evidence & citations 8 cited values

Every value below carries the sentence it was read from. 4 sources stand behind the page.

FieldValueCited text
Known as Levonadifloxacin “levonadifloxacin (active drug) and the sulfate metabolite” NCT02244827 ↗
1

NCT03405064 ↗
Known as (s)-(-)-nadifloxacin ChEMBL registry synonym — accepted as the source's own label CHEMBL190561 ↗
Known as Levonadifloxacina ChEMBL registry synonym — accepted as the source's own label CHEMBL190561 ↗
Known as Levonadifloxacine ChEMBL registry synonym — accepted as the source's own label CHEMBL190561 ↗
Known as WCK-771 FREE BASE ChEMBL registry synonym — accepted as the source's own label CHEMBL190561 ↗
Modality Small molecule “belonging to the benzoquinolizine subclass of quinolone.” PMID 32738837 ↗ Aug 2020
Route Intravenous “It is developed for oral or intravenous administration for the treatment of infections caused by Gram-positive organisms including methicillin-resistant Staphylococcus aureus (MRSA).” PMID 32738837 ↗ Aug 2020
Route Oral “It is developed for oral or intravenous administration for the treatment of infections caused by Gram-positive organisms including methicillin-resistant Staphylococcus aureus (MRSA).” PMID 32738837 ↗ Aug 2020